Patents by Inventor James A. Grattan
James A. Grattan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140066516Abstract: The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent.Type: ApplicationFiled: November 6, 2013Publication date: March 6, 2014Applicant: GLAXOSMITHKLINE, LLCInventors: Geoffrey Douglas Clarke, Timothy James Grattan, Ian Burnett
-
Patent number: 8604084Abstract: The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent.Type: GrantFiled: July 29, 2009Date of Patent: December 10, 2013Assignee: GlaxoSmithKline, LLCInventors: Geoffrey Douglas Clarke, Timothy James Grattan, Ian Burnett
-
Publication number: 20110301243Abstract: The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent.Type: ApplicationFiled: July 29, 2009Publication date: December 8, 2011Inventors: Geoffrey Douglas Clarke, Timothy James Grattan, Ian Burnett
-
Patent number: 7993673Abstract: A dosage form such as a swallow tablet or a capsule formulation is described comprising paracetamol, low levels of sodium bicarbonate or potassium bicarbonate or mixtures thereof, and at least one pharmaceutically acceptable excipient.Type: GrantFiled: June 3, 2002Date of Patent: August 9, 2011Assignee: SmithKline Beecham LimitedInventor: Timothy James Grattan
-
Publication number: 20110177168Abstract: A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.Type: ApplicationFiled: March 29, 2011Publication date: July 21, 2011Inventors: Shing Yue CHAN, Timothy James GRATTAN, Bounkhiene SENGMANEE
-
Patent number: 7943170Abstract: A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.Type: GrantFiled: April 12, 2001Date of Patent: May 17, 2011Assignee: SmithKline Beecham LimitedInventors: Shing Yue Chan, Timothy James Grattan, Bounkhiene Sengmanee
-
Publication number: 20040202716Abstract: A pharmaceutical composition comprising an immediate release phase and a sustained release phase of paracetamol is described which has a unique in vitro dissolution profile resulting in advantageous pharmacokinetic properties.Type: ApplicationFiled: June 6, 2003Publication date: October 14, 2004Inventors: Shing Yue Chan, Timothy James Grattan, Bounkhiene Sengmanee
-
Publication number: 20040170681Abstract: A dosage form such as a swallow tablet or a capsule formulation is described comprising paracetamol, low levels of sodium bicarbonate or potassium bicarbonate or mixtures thereof, and at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: December 3, 2003Publication date: September 2, 2004Inventor: Timothy James Grattan
-
Patent number: 6316025Abstract: The present invention relates to a swallow tablet or capsule formulation comprising paracetamol, sodium bicarbonate, and at least one pharmaceutically acceptable excipient.Type: GrantFiled: September 2, 1999Date of Patent: November 13, 2001Assignee: SmithKline Beecham plcInventor: Timothy James Grattan
-
Patent number: 5866162Abstract: A pharmaceutical composition for oral consumption in liquid form is provided, characterized in that the composition contains a drug, preferably a lipophilic NSAID, complexed to .beta.-cyclodextrin in a formulation also containing an acid-base couple, preferably an effervescent acid-base couple. The weight of the acid-base couple is greater than 1% of the weight of water in which the composition is to be dissolved, and provides an acid or neutral pH.Type: GrantFiled: April 9, 1997Date of Patent: February 2, 1999Assignee: SmithKline Beecham p.l.c.Inventor: Timothy James Grattan
-
Patent number: 4337339Abstract: Folic acid derivatives, such as radiolabeled pteroyltyrosine, are conveniently synthesized from either pteroic acid or by the direct condensation of 6-formylpterin with p-aminobenzoyltyrosine methyl ester. The radioiodinated derivatives are particularly useful in competitive protein binding and radioimmuno-assays of folate compounds.Type: GrantFiled: October 31, 1979Date of Patent: June 29, 1982Assignee: Baker Instruments Corp.Inventors: Peter R. Farina, James A. Grattan
-
Patent number: 4326060Abstract: Folic acid derivatives, such as radiolabeled pteroyltyrosine, are conveniently synthesized from either pteroic acid or by the direct condensation of 6-formylpterin with p-aminobenzoyltyrosine methyl ester. The radioiodinated derivatives are particularly useful in competitive protein binding and radioimmuno-assays of folate compounds.Type: GrantFiled: October 31, 1979Date of Patent: April 20, 1982Assignee: Baker Instruments CorporationInventors: Peter R. Farina, James A. Grattan
-
Patent number: 4314988Abstract: Folic acid derivatives, such as radiolabeled pteroyltyrosine, are conveniently synthesized from either pteroic acid or by the direct condensation of 6-formylpterin with p-aminobenzoyltyrosine methyl ester. The radioiodinated derivatives are particularly useful in competitive protein binding and radioimmuno-assays of folate compounds.Type: GrantFiled: October 31, 1979Date of Patent: February 9, 1982Assignee: Baker Instruments Corp.Inventors: Peter R. Farina, James A. Grattan
-
Patent number: 4298735Abstract: Folic acid derivatives, such as radiolabeled pteroyltyrosine, are conveniently synthesized from either pteroic acid or by the direct condensation of 6-formylpterin with p-aminobenzoyltyrosine methyl ester. The radioiodinated derivatives are particularly useful in competitive protein binding and radioimmuno-assays of folate compounds.Type: GrantFiled: April 30, 1979Date of Patent: November 3, 1981Assignee: Union Carbide CorporationInventors: Peter R. Farina, James A. Grattan